Anavex Life Sciences Corp. (FRA:12X1)

Market Cap	328.76M
Revenue (ttm)	n/a
Net Income (ttm)	-39.53M
Shares Out	n/a
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	364
Open	3.379
Previous Close	3.310
Day's Range	3.379 - 3.379
52-Week Range	2.261 - 13.250
Beta	n/a
RSI	50.58
Earnings Date	Feb 13, 2026

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 12X1

Financial Performance

Financial numbers in USD